IGC Pharma announced that its Phase 2 CALMA trial for the Alzheimer’s agitation candidate IGC‑AD1 will now include the Grupo de Neurociencias de Antioquia (GNA) in Colombia. The addition expands the trial’s geographic footprint into South America and brings in a patient cohort that is enriched for genetically linked Alzheimer’s, a key demographic for the drug’s target population.
The expansion is strategically designed to strengthen the trial’s statistical power and generalizability. By enrolling patients from Colombia, IGC Pharma gains access to a broader genetic diversity that can improve the robustness of efficacy and safety signals, a factor that regulators and potential partners scrutinize closely. The company’s CEO, Ram Mukunda, noted that GNA’s expertise in longitudinal Alzheimer’s cohorts and biomarker research will provide a high‑caliber research environment and accelerate data collection.
Enrollment in the CALMA trial is already at roughly 70 % of the planned target, and the company expects to complete enrollment by mid‑2026. The 70 % milestone, reported earlier in February, was a positive driver for investor sentiment because it demonstrates operational execution and positions the trial for a 2026 readout. The Colombian site is expected to contribute a significant portion of the remaining enrollment, further tightening the timeline for data analysis.
IGC Pharma’s financial position remains a critical backdrop to the expansion. The company has raised capital in January 2026 and maintains a $12 million credit line, but it continues to report net losses—$1.8 million in the third quarter of fiscal 2025 versus $5.8 million a year earlier. The announcement underscores the urgency of securing a partnership before the 12‑month cash runway expires, a factor that could influence future funding and partnership negotiations.
The market reaction to the enrollment progress earlier in February was modestly positive, with a 1.5 % lift in the company’s stock, reflecting investor confidence in the trial’s momentum. The Colombian expansion is expected to reinforce that sentiment by adding geographic and genetic depth to the study, potentially enhancing the attractiveness of IGC Pharma to strategic partners and regulators alike.
Management emphasized that the trial’s expansion aligns with the company’s broader strategy of leveraging AI-driven clinical trial optimization. By integrating GNA’s data infrastructure, IGC Pharma aims to accelerate patient recruitment and streamline biomarker collection, which could reduce time‑to‑market for IGC‑AD1 if the trial meets its primary endpoints.
In summary, the Colombian expansion is a material development that strengthens the clinical program’s scientific rigor and operational execution while highlighting the company’s ongoing need to secure external funding or a partnership to sustain its pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.